Drug Trial Radar · NCT04255277
To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.
Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
97
Actual
Start
Jan 31, 2020
Primary completion
Sep 14, 2021
Study completion Oct 18, 2021
Sponsor
- Lead sponsor
- Viatris Innovation GmbHIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, double-blind for cenerimod, open-label for moxifloxacin, placebo- and moxifloxacin-controlled, parallel-group study to investigate the effect of cenerimod on the duration of the QT interval in healthy male and female participants. Participants will be randomly assigned to one of the 4 treatments: placebo, cenerimod 0.5 mg, cenerimod 4 mg or moxifloxacin.
Conditions
- Healthy Subjects
Interventions
Combined oral contraceptives (COC)Drug
A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.
Moxifloxacin 400mgDrug
A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.
Cenerimod 0.5 mgDrug
This will be administered orally as a film-coated tablet in the morning.
Cenerimod 4 mgDrug
This will be administered orally as a film-coated tablet in the morning.
Charcoal, activatedOther
Granules for oral suspension will be used and administered open-label.
Matching PlaceboDrug
Cenerimod matching placebo tablets will be administered once daily orally in the morning.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Placebo-corrected, change-from-baseline QTcF (ΔΔQTcF)Time frame: Day 6, 7, 14, 21, 35, and 56.
- Maximum plasma concentration (Cmax): levonorgestrelTime frame: Day 1 to Day 3; Day 42 to Day 44
- Maximum plasma concentration (Cmax): ethinylestradiolTime frame: Day 1 to Day 3; Day 42 to Day 44
- Time to reach Cmax (tmax): levonorgestrelTime frame: Day 1 to Day 3; Day 42 to Day 44
- Time to reach Cmax (tmax): ethinylestradiolTime frame: Day 1 to Day 3; Day 42 to Day 44
- The area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf): levonorgestrelTime frame: Day 1 to Day 3; Day 42 to Day 44
- The area under the plasma concentration-time curve (AUC) from zero to t (AUC0-t): levonorgestrelTime frame: Day 1 to Day 3; Day 42 to Day 44
- The area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf): ethinylestradiolTime frame: Day 1 to Day 3; Day 42 to Day 44
- The area under the plasma concentration-time curve (AUC) from zero to t (AUC0-t): ethinylestradiolTime frame: Day 1 to Day 3; Day 42 to Day 44
- Terminal elimination half-life (t1/2): levonorgestrelTime frame: Day 56 to Day 68
- Terminal elimination half-life (t1/2): ethinylestradiolTime frame: Day 56 to Day 68
- Terminal elimination half-life (t1/2): cenerimodTime frame: Day 56 to Day 68
- Area under the plasma concentration-time curve (AUC) from Day 56 to infinity (AUC56-inf) for cenerimodTime frame: Day 56 to Day 68
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site 1
Rennes, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.